DOW JONES26,957.59-123.77 -0.46%
S&P 5003,116.39-11.82 -0.38%
NASDAQ8,980.78+15.16 0.17%

JP Morgan Maintains Overweight on Coherus BioSciences, Raises Price Target to $35

JP Morgan maintains Coherus BioSciences (NASDAQ:CHRS) with a Overweight and raises the price target from $33 to $35.

Benzinga · 02/06/2020 13:34

JP Morgan maintains Coherus BioSciences (NASDAQ:CHRS) with a Overweight and raises the price target from $33 to $35.